JP2016514148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514148A5 JP2016514148A5 JP2016501850A JP2016501850A JP2016514148A5 JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5 JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- nos
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 98
- 208000034578 Multiple myelomas Diseases 0.000 claims 22
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 22
- 238000011282 treatment Methods 0.000 claims 20
- 229960003957 dexamethasone Drugs 0.000 claims 15
- 229960002438 carfilzomib Drugs 0.000 claims 13
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 13
- 108010021331 carfilzomib Proteins 0.000 claims 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 10
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 10
- -1 dexamethasone compound Chemical class 0.000 claims 9
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 6
- 229940121354 immunomodulator Drugs 0.000 claims 6
- 230000002584 immunomodulator Effects 0.000 claims 6
- 239000003207 proteasome inhibitor Substances 0.000 claims 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 5
- 230000006907 apoptotic process Effects 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 3
- 229960001467 bortezomib Drugs 0.000 claims 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 3
- 229960004942 lenalidomide Drugs 0.000 claims 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- 229960003433 thalidomide Drugs 0.000 claims 3
- 238000011260 co-administration Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778540P | 2013-03-13 | 2013-03-13 | |
| US61/778,540 | 2013-03-13 | ||
| US201361808381P | 2013-04-04 | 2013-04-04 | |
| US61/808,381 | 2013-04-04 | ||
| PCT/US2014/025441 WO2014159911A1 (en) | 2013-03-13 | 2014-03-13 | Compositions comprising anti-cd38 antibodies and carfilzomib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514148A JP2016514148A (ja) | 2016-05-19 |
| JP2016514148A5 true JP2016514148A5 (OSRAM) | 2017-06-15 |
| JP6279065B2 JP6279065B2 (ja) | 2018-02-14 |
Family
ID=51625288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501850A Active JP6279065B2 (ja) | 2013-03-13 | 2014-03-13 | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160022813A1 (OSRAM) |
| EP (2) | EP3769783A1 (OSRAM) |
| JP (1) | JP6279065B2 (OSRAM) |
| KR (2) | KR20210043006A (OSRAM) |
| CN (3) | CN105407921A (OSRAM) |
| AU (1) | AU2014244333B2 (OSRAM) |
| CA (1) | CA2904630A1 (OSRAM) |
| ES (1) | ES2808565T3 (OSRAM) |
| IL (2) | IL292978A (OSRAM) |
| MX (1) | MX373308B (OSRAM) |
| MY (1) | MY175418A (OSRAM) |
| PL (1) | PL2968555T3 (OSRAM) |
| PT (1) | PT2968555T (OSRAM) |
| RU (2) | RU2723937C2 (OSRAM) |
| SG (3) | SG10201707464SA (OSRAM) |
| WO (1) | WO2014159911A1 (OSRAM) |
| ZA (1) | ZA201507310B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| PL2900232T3 (pl) | 2012-09-25 | 2018-05-30 | Morphosys Ag | Kombinacje i ich zastosowania |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| MA39070A1 (fr) * | 2014-07-31 | 2017-11-30 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN112703038B (zh) * | 2018-07-10 | 2025-07-29 | 赛诺菲 | 靶向CD38和TGF-β的抗癌组合疗法 |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| IL293563A (en) | 2019-12-05 | 2022-08-01 | Sanofi Aventis Us Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| BR112022010907A2 (pt) * | 2019-12-06 | 2022-10-18 | Sanofi Aventis Us Llc | Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| DE69800716T2 (de) | 1997-04-14 | 2001-09-20 | Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20070042436A1 (en) * | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| RU2402568C2 (ru) * | 2004-02-06 | 2010-10-27 | МорфоСис АГ | Человеческие анти-cd38-антитела и их применение |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US8129346B2 (en) | 2004-04-15 | 2012-03-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| ES2549763T3 (es) | 2004-12-07 | 2015-11-02 | Onyx Therapeutics, Inc. | Composición para inhibición del proteasoma |
| JP2008530244A (ja) * | 2005-02-18 | 2008-08-07 | メダレックス， インク． | フコシル残基を欠くｃｄ３０に対するモノクローナル抗体 |
| CN103554260A (zh) * | 2005-10-12 | 2014-02-05 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| SI2068930T1 (sl) * | 2006-08-07 | 2013-01-31 | Abbott Biotherapeutics Corp. | Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma |
| RU2456990C2 (ru) * | 2006-09-15 | 2012-07-27 | Янссен Фармацевтика Нв | Комбинации специфичных ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| SG191679A1 (en) * | 2008-06-16 | 2013-07-31 | Immunogen Inc | Novel synergistic effects |
| JP5675629B2 (ja) * | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| ES2674719T3 (es) * | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Terapias para neoplasias hematológicas |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| MX2011011684A (es) * | 2009-05-06 | 2012-01-20 | Biotest Ag | Usos de inmunoconjugados dirigidos a cd138. |
| BR112013006769B1 (pt) * | 2010-09-27 | 2021-02-02 | Morphosys Ag | combinação sinérgica |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| US9272014B2 (en) * | 2011-03-29 | 2016-03-01 | Texas Tech University System | Galectin-3C combination therapy for human cancer |
| MA39070A1 (fr) * | 2014-07-31 | 2017-11-30 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
-
2014
- 2014-03-13 EP EP20180210.5A patent/EP3769783A1/en not_active Withdrawn
- 2014-03-13 ES ES14773270T patent/ES2808565T3/es active Active
- 2014-03-13 MX MX2015012297A patent/MX373308B/es active IP Right Grant
- 2014-03-13 IL IL292978A patent/IL292978A/en unknown
- 2014-03-13 JP JP2016501850A patent/JP6279065B2/ja active Active
- 2014-03-13 WO PCT/US2014/025441 patent/WO2014159911A1/en not_active Ceased
- 2014-03-13 KR KR1020217010487A patent/KR20210043006A/ko not_active Ceased
- 2014-03-13 CA CA2904630A patent/CA2904630A1/en not_active Abandoned
- 2014-03-13 KR KR1020157027249A patent/KR102241868B1/ko active Active
- 2014-03-13 US US14/775,641 patent/US20160022813A1/en not_active Abandoned
- 2014-03-13 PT PT147732705T patent/PT2968555T/pt unknown
- 2014-03-13 CN CN201480024843.3A patent/CN105407921A/zh active Pending
- 2014-03-13 RU RU2018134595A patent/RU2723937C2/ru active
- 2014-03-13 IL IL241407A patent/IL241407B/en unknown
- 2014-03-13 AU AU2014244333A patent/AU2014244333B2/en active Active
- 2014-03-13 SG SG10201707464SA patent/SG10201707464SA/en unknown
- 2014-03-13 PL PL14773270T patent/PL2968555T3/pl unknown
- 2014-03-13 CN CN202010773679.3A patent/CN112043826A/zh active Pending
- 2014-03-13 MY MYPI2015702949A patent/MY175418A/en unknown
- 2014-03-13 CN CN202510798995.9A patent/CN120860201A/zh active Pending
- 2014-03-13 SG SG11201506956TA patent/SG11201506956TA/en unknown
- 2014-03-13 SG SG10201913777XA patent/SG10201913777XA/en unknown
- 2014-03-13 RU RU2015143462A patent/RU2670127C2/ru active
- 2014-03-13 EP EP14773270.5A patent/EP2968555B1/en active Active
-
2015
- 2015-10-01 ZA ZA2015/07310A patent/ZA201507310B/en unknown
-
2016
- 2016-12-22 US US15/389,279 patent/US20170106085A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,693 patent/US20190321471A1/en not_active Abandoned
-
2021
- 2021-05-19 US US17/324,478 patent/US20220088194A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514148A5 (OSRAM) | ||
| JP2016506388A5 (OSRAM) | ||
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2017048208A5 (OSRAM) | ||
| RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| JP2016536314A5 (OSRAM) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
| JP2017528462A5 (OSRAM) | ||
| MX2018007704A (es) | Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. | |
| EA201390993A1 (ru) | Антитела к cd38 | |
| HRP20191115T1 (hr) | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora | |
| JP2010500370A5 (OSRAM) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2015530399A5 (OSRAM) | ||
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| TW201613975A (en) | Methods for treating multiple myeloma | |
| CO2018005983A2 (es) | Compuestos de isoindol | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| JP2020533383A5 (OSRAM) |